3B Pharmaceuticals GmbH
Magnusstraße 11, 12489 Berlin
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical program from 3B Pharmaceuticals and to discovery program for three additional ...
Harnessing the structural plethora of peptides to discover novel therapeutics
On the perseverance of entrepreneurs and scientists from Adlershof
Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology